Home > Insider Trading > Filing (0000899243-17-027016)

Filing Details

Accession Number:: 0000899243-17-027016
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-11-20 17:43:36
Reporting Period:: 2017-11-20

Accepted Time:: 2017-11-20 17:43:36
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1501697	Arsanis Inc.	ASNS	Biological Products, (No Disgnostic Substances) (2836)	273181608

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1722050	Claudio Nessi	C/O Neomed Innovation V L.p. 13 Castle Street St Helier Y9 JE4 5UT		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-11-20	246,682	$0.00	246,682	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2017-11-20	41,878	$0.00	288,560	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2017-11-20	279,079	$0.00	567,639	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2017-11-20	300,000	$10.00	867,639	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Convertible Preferred Stock	Disposition	2017-11-20	552,487	$0.00	246,682	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2017-11-20	84,040	$0.00	41,878	$0.00
Common Stock	Series D Convertible Preferred Stock	Disposition	2017-11-20	952,497	$0.00	279,079	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.
The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.
The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.
The reported securities are held of record by NeoMed Innovation V L.P. Claudio Nessi, a member of our board of directors, is the Managing Partner of NeoMed Management (Jersey) Limited, which is the Investment Manager to NeoMed Innovation V L.P. By virtue of such relationship, Dr. Nessi may be deemed to have voting and investment power with respect to the shares held by NeoMed Innovation V L.P. Dr. Nessi disclaims beneficial ownership of the shares held by NeoMed Innovation V L.P., except to the extent of its his pecuniary interest therein, if any.